- Home
- EHGO vs MDXH Comparison
EHGO vs MDXH Comparison
Compare EHGO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHGO
- MDXH
- Stock Information
- Founded
- EHGO 2015
- MDXH 2003
- Country
- EHGO China
- MDXH Belgium
- Employees
- EHGO N/A
- MDXH N/A
- Industry
- EHGO
- MDXH
- Sector
- EHGO
- MDXH
- Exchange
- EHGO NYSE
- MDXH Nasdaq
- Market Cap
- EHGO 23.0M
- MDXH 84.6M
- IPO Year
- EHGO 2024
- MDXH 2021
- Fundamental
- Price
- EHGO $0.80
- MDXH $2.18
- Analyst Decision
- EHGO
- MDXH Buy
- Analyst Count
- EHGO 0
- MDXH 1
- Target Price
- EHGO N/A
- MDXH $6.00
- AVG Volume (30 Days)
- EHGO 3.3M
- MDXH 61.1K
- Earning Date
- EHGO 07-22-2025
- MDXH 08-20-2025
- Dividend Yield
- EHGO N/A
- MDXH N/A
- EPS Growth
- EHGO N/A
- MDXH N/A
- EPS
- EHGO N/A
- MDXH N/A
- Revenue
- EHGO $15,393,105.00
- MDXH $94,507,000.00
- Revenue This Year
- EHGO N/A
- MDXH $23.51
- Revenue Next Year
- EHGO N/A
- MDXH $17.68
- P/E Ratio
- EHGO N/A
- MDXH N/A
- Revenue Growth
- EHGO N/A
- MDXH 25.46
- 52 Week Low
- EHGO $0.71
- MDXH $1.35
- 52 Week High
- EHGO $5.50
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- EHGO N/A
- MDXH 52.06
- Support Level
- EHGO N/A
- MDXH $2.09
- Resistance Level
- EHGO N/A
- MDXH $2.22
- Average True Range (ATR)
- EHGO 0.00
- MDXH 0.10
- MACD
- EHGO 0.00
- MDXH -0.01
- Stochastic Oscillator
- EHGO 0.00
- MDXH 59.52
About EHGO ESHALLGO INC
Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.